New & Noteworthy

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Value-Based Healthcare in the UK

Jill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.

Beyond the Blame Game: How Pharma is Learning to Collaborate

Pharma stakeholders are putting more energy into building partnerships that can deliver high-quality care to the greatest number of people, writes Novo Nordisk’s Jesper Høiland.

What’s Ahead for 2015? Pharm Exec's Industry Outlook

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

The Industry's Score on Five Key Performance Measures

Five years after Editor William Looney's first Pharm Exec column, he assesses the progress of the industry since 2010 in five key performance measures.

Europe

Former Roche CEO Joins Portugal's BIAL

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Value-Based Healthcare in the UK

Jill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.

Global

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

VC Optimism to China: Leading Biologics Company Raises $100m C Round

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

Got Ideas? Go North!

The Canadian R&D industry, which boasts a rich history of drug innovation, celebrates a series of anniversaries.

Pharma in Cuba: An Untapped Market?

If you’re like us at PharmExec, you’ve been reading the news of potentially thawing US/Cuban relations, and you’re wondering, how long before the flag of Cuba graces the Hall of nations at BIO International Convention?

Country Report: Algeria

Once considered a healthcare backwater, Algeria's expanding pharmaceuticals market is taking the African continent by storm.

Ireland's Celtic Tiger: Back on the Hunt

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

Strategy

Supply Chain Analytics: Pharma’s Next Big Bet

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.

Sanofi’s Big Bet on Integrated Patient Care

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

Pharma Manufacturing Outsourcing: 2014 in Review

Eric Langer assesses the findings of BioPlan’s 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.

Express Scripts to Center Stage

Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

Blogs

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

2015: Blockbuster Year for M&A in Asia

The healthcare landscape in Asia-Pacific is expected to continue grow strongly in 2015, according to a report by Frost & Sullivan.

VC Optimism to China: Leading Biologics Company Raises $100m C Round

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

Shire CEO – Almost Ideal Timing for NPS Deal

Fresh off Shire’s announcement to purchase NPS, CEO Dr. Flemming Ornskov sat down with PharmExec in San Francisco during the JP Morgan Healthcare Conference.

Orphan Drug Prices Face Increased Scrutiny

With the FDA approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny.

News Update

Former Roche CEO Joins Portugal's BIAL

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

$5 Million Payout for Viehbacher

Sanofi has agreed to pay its former CEO Chris Viehbacher a total of Euro 4.44 million ($5.06 million).

Colorectal Cancer Market to Grow Despite Avastin Patent Expiration

The value of the Colorectal Cancer (CRC) therapeutics market will increase from $8.3 billion in 2013 to $9.4 billion by 2020, according to a report from GBI Research.

New Advisory Board for CPhI Worldwide

CPhI Worldwide is launching an international advisory board.

2015: Blockbuster Year for M&A in Asia

The healthcare landscape in Asia-Pacific is expected to continue grow strongly in 2015, according to a report by Frost & Sullivan.

Regulatory

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Politics & Prices Dominate 2015 Agenda

Transparency, quality, collaboration key to filling pipelines, gaining reimbursement.

FDA Advisors Unanimously Approve Sandoz Biosimilar

The main surprise at the Jan. 7, 2015 meeting of FDA’s Oncologic Drugs Advisory Committee was the panel’s strong support for a drug developed under a very different model from most cancer therapies, writes Jill Wechsler.

Sales & Marketing

What's Wrong with the Annual Sales Kickoff: And How to Fix it

New ways for pharma to make sure its sales reps stay sharp amid a flood of new information and a more complex selling climate. By Duncan Lennox.

Digital's Place in the Pharma Marketing Mix

The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.

OTC Drug Advertising: Alfred Hitchcock Style

The legendary director's on-screen attitude to his TV show's sponsor, Bristol-Myers, caused some consternation—until the drugmaker saw the results.

Social Media and the In-House Counsel

What is and what should be keeping you up at night.

R&D

Pharmacies — A New Patient Education Opportunity

Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.

Open Innovation in Pharma: Defining the Dialogue

There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?